Cathay Biotech Stock Current Valuation
| 688065 Stock | 42.02 0.48 1.13% |
Valuation analysis of Cathay Biotech helps investors to measure Cathay Biotech's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Cathay Biotech's Cash is projected to increase significantly based on the last few years of reporting. The current year's Other Non Cash Items is expected to grow to about 10.3 M, whereas Change In Cash is projected to grow to (1.2 B). Fundamental drivers impacting Cathay Biotech's valuation include:
Price Book 2.1528 | Enterprise Value 21.2 B | Enterprise Value Ebitda 44.5485 | Price Sales 8.8696 | Trailing PE 61.7941 |
Overvalued
Today
Please note that Cathay Biotech's price fluctuation is not too volatile at this time. Calculation of the real value of Cathay Biotech is based on 3 months time horizon. Increasing Cathay Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cathay Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cathay Stock. However, Cathay Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 42.02 | Real 36.0 | Hype 41.87 | Naive 44.48 |
The real value of Cathay Stock, also known as its intrinsic value, is the underlying worth of Cathay Biotech Company, which is reflected in its stock price. It is based on Cathay Biotech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cathay Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cathay Biotech helps investors to forecast how Cathay stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cathay Biotech more accurately as focusing exclusively on Cathay Biotech's fundamentals will not take into account other important factors: Cathay Biotech Company Current Valuation Analysis
Cathay Biotech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cathay Biotech Current Valuation | 21.17 B |
Most of Cathay Biotech's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cathay Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Cathay Biotech has a Current Valuation of 21.17 B. This is 85.58% higher than that of the Chemicals sector and 52.39% higher than that of the Materials industry. The current valuation for all China stocks is 27.37% lower than that of the firm.
Cathay Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cathay Biotech's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cathay Biotech could also be used in its relative valuation, which is a method of valuing Cathay Biotech by comparing valuation metrics of similar companies.Cathay Biotech is currently under evaluation in current valuation category among its peers.
Cathay Fundamentals
| Return On Equity | 0.026 | ||||
| Return On Asset | 0.0106 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 21.17 B | ||||
| Shares Outstanding | 583.38 M | ||||
| Shares Owned By Insiders | 61.34 % | ||||
| Shares Owned By Institutions | 11.09 % | ||||
| Price To Book | 2.15 X | ||||
| Price To Sales | 8.87 X | ||||
| Revenue | 2.11 B | ||||
| Gross Profit | 2.44 B | ||||
| EBITDA | 608.83 M | ||||
| Net Income | 366.52 M | ||||
| Total Debt | 1.53 B | ||||
| Book Value Per Share | 19.74 X | ||||
| Cash Flow From Operations | 569.45 M | ||||
| Earnings Per Share | 0.68 X | ||||
| Target Price | 69.35 | ||||
| Number Of Employees | 1.8 K | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 24.51 B | ||||
| Total Asset | 18.83 B | ||||
| Retained Earnings | 2.07 B | ||||
| Working Capital | 4.16 B | ||||
| Annual Yield | 0 % | ||||
| Net Asset | 18.83 B | ||||
| Last Dividend Paid | 0.19 |
About Cathay Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cathay Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cathay Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cathay Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Cathay Stock
Cathay Biotech financial ratios help investors to determine whether Cathay Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cathay with respect to the benefits of owning Cathay Biotech security.